Skip to main content
main-content

01.12.2017 | Original Article | Ausgabe 1/2017 Open Access

Archives of Osteoporosis 1/2017

Effect of bisphosphonate initiation at week 2 versus week 12 on short-term functional recovery after femoral neck fracture: a randomized controlled trial

Zeitschrift:
Archives of Osteoporosis > Ausgabe 1/2017
Autoren:
Aasis Unnanuntana, Panai Laohaprasitiporn, Atthakorn Jarusriwanna
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s11657-017-0321-8) contains supplementary material, which is available to authorized users.

Abstract

Summary

The appropriate time to initiate bisphosphonate treatment after a fragility fracture has not yet been established. In this study, we found no significant differences in short-term functional recovery between femoral neck fracture patients who received bisphosphonate treatment at 2 versus 12 weeks after hemiarthroplasty.

Introduction

Bisphosphonate is the mainstay therapy for prevention and treatment of osteoporosis. The aim of this study was to investigate the effect of bisphosphonate initiation on short-term functional recovery in femoral neck fracture patients at 2 versus 12 weeks after hemiarthroplasty.

Methods

One hundred patients were randomly allocated into two groups in a parallel group designed, randomized, controlled trial. Both groups received risedronate 35 mg/week at either 2 or 12 weeks after hemiarthroplasty. All patients received calcium and vitamin D supplementation. Functional recovery was assessed by de Morton Mobility Index, Barthel Index, EuroQol 5D, visual analog scale, 2-min walk test, and timed get-up-and-go test at 2 weeks, 3 months, and 1 year after surgery.

Results

At the 3-month follow-up, all functional outcome measures showed significant improvement in both groups. There were no statistically significant differences in any of the functional outcomes between groups at both the 3-month and 1-year follow-ups. Although patients who received bisphosphonate initiation at week 2 had lower serum calcium level at 3 months and more overall adverse events than patients in the week 12 group, no patients in either group discontinued their prescribed medications.

Conclusions

While underpowered, the findings of this study suggest that there were no significant differences in short-term functional recovery or significant adverse events between the two bisphosphonate groups. Thus, the initiation of bisphosphonate therapy may be considered as early as 2 weeks after femoral neck fracture. It is important that low serum calcium and vitamin D status must be corrected with calcium and vitamin D supplementation prior to or at the time of bisphosphonate initiation.

Clinical trial registration number

This study was registered in the database via the Protocol Registration and Results System (PRS) (NCT02148848).

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Zusatzmaterial
ESM 1 (DOCX 29 kb).
11657_2017_321_MOESM1_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Archives of Osteoporosis 1/2017 Zur Ausgabe

Neu im Fachgebiet Orthopädie und Unfallchirurgie

23.05.2019 | DAC 2019 | Kongressbericht | Nachrichten

Ist uns „Sichtung“ überhaupt möglich?

22.05.2019 | DAC 2019 | Kongressbericht | Nachrichten

So geht gute Notfallmedizin – so ginge es noch besser

21.05.2019 | DAC 2019 | Kongressbericht | Nachrichten

Cannabis als Medikament?

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Orthopädie und Unfallchirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise